PMID- 19555216
OWN - NLM
STAT- MEDLINE
DCOM- 20100107
LR  - 20130102
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 31
IP  - 3
DP  - 2009
TI  - Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable 
      vaccine therapy.
PG  - 468-76
LID - 10.1080/08923970902795203 [doi]
AB  - Recent research has indicated that MUC4 plays an important role in the 
      development of many tumors and may prove useful as a novel cancer immunotherapy 
      target. We aimed to identify HLA-A*0201-restrictive cytotoxic T lymphocyte (CTL) 
      epitopes of the cancer-associated antigen MUC4. The MUC4 sequence was scanned for 
      immunogenic peptides using HLA-binding prediction software. Dendritic cells (DCs) 
      from peripheral blood mononuclear cells (PBMCs) were induced by cytokines. Five 
      possible CTL epitopes were selected by software analysis, synthesized, and used 
      to pulse mature DCs. The CD8(+) T cells from PBMCs from an HLA-A*0201 healthy 
      donor were stimulated with autologous MUC4-peptide-loaded DCs and expanded in 
      vitro. T cell activation was assessed by ELISPOT, and cytotoxicity was determined 
      by (51)chromium ((51)Cr)-release assays. Our results show that CTLs induced by 
      peptide P01204 could lyse T2 cells pulsed with peptide P01204 and HCT-116 cells 
      (MUC4(+), HLA-A2(+)). Compared with a control peptide, P01204 increased the 
      number of IFN-gamma producing T cells. Overall, these results suggest that P01204 
      is a novel HLA-A*0201-restrictive CTL epitope of the cancer-associated antigen 
      MUC4. This will provide a foundation for the development of tumor-specific 
      peptide vaccines.
FAU - Wu, Junli
AU  - Wu J
AD  - Department of General Surgery, First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, PR China.
FAU - Wei, Jishu
AU  - Wei J
FAU - Meng, Kai
AU  - Meng K
FAU - Chen, Jianmin
AU  - Chen J
FAU - Gao, Wentao
AU  - Gao W
FAU - Zhang, Jingjing
AU  - Zhang J
FAU - Xu, Zekuan
AU  - Xu Z
FAU - Miao, Yi
AU  - Miao Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (MUC4 protein, human)
RN  - 0 (Mucin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
CIN - Immunopharmacol Immunotoxicol. 2013 Feb;35(1):202-3. PMID: 22957748
MH  - Antigens, Neoplasm/immunology/*pharmacology
MH  - Cancer Vaccines/immunology/*pharmacology
MH  - Cell Line, Tumor
MH  - Dendritic Cells
MH  - Epitope Mapping/methods
MH  - Epitopes, T-Lymphocyte/immunology/*pharmacology
MH  - Female
MH  - HLA-A Antigens/*immunology
MH  - HLA-A2 Antigen
MH  - Humans
MH  - Interferon-gamma/immunology
MH  - Male
MH  - Mucin-4/immunology/*pharmacology
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2009/06/27 09:00
MHDA- 2010/01/08 06:00
CRDT- 2009/06/27 09:00
PHST- 2009/06/27 09:00 [entrez]
PHST- 2009/06/27 09:00 [pubmed]
PHST- 2010/01/08 06:00 [medline]
AID - 10.1080/08923970902795203 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2009;31(3):468-76. doi: 10.1080/08923970902795203.